VIDEO: Axpaxli for wet AMD shows durability, safety in phase 1 trial
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilsher S. Dhoot, MD, discusses 52-week phase 1 data for Axpaxli for the treatment of neovascular age-related macular degeneration.
In the trial, patients were randomly assigned to treatment with either Axpaxli (axitinib intravitreal implant, Ocular Therapeutix), also known as OTX-TKI, or aflibercept, with Axpaxli demonstrating “fantastic durability results” in addition to a positive safety profile.
“There was maintenance of visual acuity in OCT parameters in this study as you might expect, with less fluctuation in the fluid curves in the Axpaxli group than the aflibercept group,” Dhoot said.
Collapse
Dhoot DS. Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related macular degeneration. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Read more about
Click Here to Manage Email Alerts